OncoMatch/Clinical Trials/NCT07015190
Neoadjuvant Darovasertib in Primary Uveal Melanoma
Is NCT07015190 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Darovasertib for uveal melanoma.
Treatment: Darovasertib — This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Melanoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: any prior treatment for uveal melanoma
Previous treatment for UM
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic Scottsdale - PPDS · Scottsdale, Arizona
- UCSD Moores Cancer Center · La Jolla, California
- Jules Stein Eye Institute · Los Angeles, California
- University of California Irvine Medical Center · Orange, California
- Stanford Comprehensive Cancer Center · Palo Alto, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07015190 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages